Crinetics says Phase 2 trial shows atumelnant cuts CAH androgen levels 67% while enabling glucocorticoid dose reduction

CRINETICS PHARMACEUTICALS, INC.

CRINETICS PHARMACEUTICALS, INC.

CRNX

0.00
  • Crinetics presented full Phase 2 adult CAH results for once-daily atumelnant at ENDO 2026.
  • Study showed sustained androgen suppression while allowing most participants to reduce steroid supplementation to physiologically normal levels.
  • Separate ENDO 2026 presentation disclosed early Phase 1b/2a data in ACTH-dependent Cushing’s syndrome showing rapid cortisol lowering, with some normalization.
  • Tolerability appeared manageable, with adverse events largely consistent with adrenal insufficiency and typically improved with replacement steroids.
  • Program moved into late-stage development, with adult and pediatric Phase 3 trials already underway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606141630OMX_____CNEWS_EN_GNW9746603_en) on June 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.